[HTML][HTML] Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab …
D Soulieres, JL Aguilar, E Chen, K Misiukiewicz… - BMC cancer, 2016 - Springer
Background Cetuximab, in combination with platinum chemotherapy plus 5-fluoruracil (5-
FU), is approved for the first-line treatment of recurrent/metastatic squamous cell carcinoma …
FU), is approved for the first-line treatment of recurrent/metastatic squamous cell carcinoma …
[PDF][PDF] Denis Soulières1, Jose Luis Aguilar2, Eric Chen3, Krzysztof Misiukiewicz4, Scott Ernst5, Hyun Jung Lee6
K Bryant, S He, CK Obasaju, SC Chang, S Chin… - 2016 - scienceopen.com
Background: Cetuximab, in combination with platinum chemotherapy plus 5-fluoruracil (5-
FU), is approved for the first-line treatment of recurrent/metastatic squamous cell carcinoma …
FU), is approved for the first-line treatment of recurrent/metastatic squamous cell carcinoma …
[PDF][PDF] Denis Soulières1, Jose Luis Aguilar2, Eric Chen3, Krzysztof Misiukiewicz4, Scott Ernst5, Hyun Jung Lee6
K Bryant, S He, CK Obasaju, SC Chang, S Chin… - 2016 - cyberleninka.org
Background: Cetuximab, in combination with platinum chemotherapy plus 5-fluoruracil (5-
FU), is approved for the first-line treatment of recurrent/metastatic squamous cell carcinoma …
FU), is approved for the first-line treatment of recurrent/metastatic squamous cell carcinoma …
Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: A randomized, double-blind safety study comparing cetuximab produced …
D Soulières, JL Aguilar, E Chen, K Misiukiewicz… - BMC Cancer, 2016 - profiles.wustl.edu
Background: Cetuximab, in combination with platinum chemotherapy plus 5-fluoruracil (5-
FU), is approved for the first-line treatment of recurrent/metastatic squamous cell carcinoma …
FU), is approved for the first-line treatment of recurrent/metastatic squamous cell carcinoma …
[PDF][PDF] Denis Soulières1, Jose Luis Aguilar2, Eric Chen3, Krzysztof Misiukiewicz4, Scott Ernst5, Hyun Jung Lee6
K Bryant, S He, CK Obasaju, SC Chang, S Chin… - 2016 - core.ac.uk
Background: Cetuximab, in combination with platinum chemotherapy plus 5-fluoruracil (5-
FU), is approved for the first-line treatment of recurrent/metastatic squamous cell carcinoma …
FU), is approved for the first-line treatment of recurrent/metastatic squamous cell carcinoma …
[HTML][HTML] Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab …
D Soulières, JL Aguilar, E Chen, K Misiukiewicz… - BMC Cancer, 2016 - ncbi.nlm.nih.gov
Background Cetuximab, in combination with platinum chemotherapy plus 5-fluoruracil (5-
FU), is approved for the first-line treatment of recurrent/metastatic squamous cell carcinoma …
FU), is approved for the first-line treatment of recurrent/metastatic squamous cell carcinoma …
Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced …
D Soulières, JL Aguilar, E Chen, K Misiukiewicz… - 2016 - pubmed.ncbi.nlm.nih.gov
Background Cetuximab, in combination with platinum chemotherapy plus 5-fluoruracil (5-
FU), is approved for the first-line treatment of recurrent/metastatic squamous cell carcinoma …
FU), is approved for the first-line treatment of recurrent/metastatic squamous cell carcinoma …
Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced …
D Soulières, JL Aguilar, E Chen, K Misiukiewicz… - tspace.library.utoronto.ca
Background Cetuximab, in combination with platinum chemotherapy plus 5-fluoruracil (5-
FU), is approved for the first-line treatment of recurrent/metastatic squamous cell carcinoma …
FU), is approved for the first-line treatment of recurrent/metastatic squamous cell carcinoma …
Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced …
D Soulières, JL Aguilar, E Chen, K Misiukiewicz… - BMC Cancer, 2016 - europepmc.org
Background Cetuximab, in combination with platinum chemotherapy plus 5-fluoruracil (5-
FU), is approved for the first-line treatment of recurrent/metastatic squamous cell carcinoma …
FU), is approved for the first-line treatment of recurrent/metastatic squamous cell carcinoma …
[HTML][HTML] Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab …
D Soulières, JL Aguilar, E Chen… - BMC …, 2016 - bmccancer.biomedcentral.com
Cetuximab, in combination with platinum chemotherapy plus 5-fluoruracil (5-FU), is
approved for the first-line treatment of recurrent/metastatic squamous cell carcinoma of the …
approved for the first-line treatment of recurrent/metastatic squamous cell carcinoma of the …